Article Details

Vigil Neuroscience Reports Second Quarter 2022 Financial - GlobeNewswire

Retrieved on: 2022-08-08 11:07:32

Tags for this article:

Click the tags to see associated articles and topics

Vigil Neuroscience Reports Second Quarter 2022 Financial - GlobeNewswire. View article details on hiswai:

Excerpt

Initiated a Phase 1 trial of VGL101 in healthy volunteers in Australia – – Received U.S. FDA orphan drug designation for VGL101 for the treatment ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up